RxDoctor Payments Data

Lisa Tully, MD

Cardiovascular Disease · Mendham, NJNPI 1043485055

Payments from drug & device makers

$2,019in general payments, 2019–2025

Across 140 payments — averaging $14.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$817
  • Merck$163
  • Amgen$144
  • Pfizer$103
  • AstraZeneca$95
  • Irhythm Technologies, Inc.$83
  • plus $615 from 18 others

What the payments were for

  • Food & beverage$2,019100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,019 in reported general payments places this provider in the 40th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$301,076
Medicare patients
1,509
Services billed
4,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban480$558,445
XareltoRivaroxaban161$173,267
EntrestoSacubitril/Valsartan124$154,213
Repatha SureclickEvolocumab76$88,102
JardianceEmpagliflozin34$51,102
MultaqDronedarone Hcl39$39,405
FarxigaDapagliflozin Propanediol22$30,053
Praluent PenAlirocumab25$17,667
Metoprolol Succinate807$13,017
Rosuvastatin Calcium931$11,934
Atorvastatin Calcium716$8,410
Pitavastatin Calcium16$7,430
Valsartan207$6,020
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide86$5,176
EdarbyclorAzilsartan Med/Chlorthalidone15$4,798

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$103$558,445480 claims
Johnson & JohnsonXarelto$51$173,267161 claims
NovartisEntresto$817$154,213124 claims
Boehringer IngelheimJardiance$62$51,10234 claims
Sanofi-aventis U.S. LLCMultaq$21$39,40539 claims
AstraZenecaFarxiga$95$30,05322 claims
Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi$43$7,80927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Mendham

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →